HELP
NASDAQ HealthcareCybin Inc. - Common Stock
Biotechnology
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
�� 市场数据
| 价格 | $7.04 |
|---|---|
| 成交量 | 3,777,187 |
| 市值 | 436.37M |
| 贝塔系数 | 0.620 |
| RSI（14日） | 63.7 |
| 200日均线 | $6.00 |
| 50日均线 | $5.17 |
| 52周最高 | $9.12 |
| 52周最低 | $3.76 |
| Forward P/E | -3.00 |
| Price / Book | 134.63 |
🎯 投资策略评分
HELP 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (69/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (10/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 HELP in your text
粘贴任何文章、记录或帖子 — 工具将提取 HELP 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.